The global Tumour Ablation Market size was estimated at USD 620.71 Mn in 2021, growing at a CAGR of 13.2% during the forecast period 2021-2027. Tumour ablation is a minimally invasive surgical method that enables treats solid tumours in which special probes are used to freeze or burn cancers without the usual surgery. The tumour ablation method is guided by the help of a CT scan, MRI Scan and ultrasound to locate and position the needle probe into the tumour which requires a tiny hole of 3mm diameter to introduce the probe. When the probe is within cancer it is attached to a generator that burns and freezes cancer. The most common cancers that are treated by this method are lung cancer, renal cancer, and liver cancer. Innovations in resources and technologies required in tumour ablation have provided ample opportunities for various pharma and electronics companies to work for the betterment of currently available technologies of tumour ablation. Innovations such as high intensity focussed ultrasound (HIFU), irreversible electroporation and image-guided procedures are rising demand for adaptation of tumour ablation. Moreover, increased focus on R&D investments, product developments, and launches, acquisitions, mergers, and collaborations are few strategies adopted by the players in the Tumour Ablation Market. For exemplary, in 2016, Medtronic launchedBarrx360 express radiofrequency ablation balloon catheter to treat Barrett’s oesophagus and in 2016 May, BTG Plc. has acquired Galil Medical, cryoablation systems, and needles manufacturer.